Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Parallel-Design, Single-Dose, Open-Label Study to Investigate the Pharmacokinetics and Safety of Tersolisib in Participants With Renal Impairment Compared With Participants With Normal Renal Function

NCT07924930 is registered in ClinicalTrials.gov with Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07924930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Parallel-Design, Single-Dose, Open-Label Study to Investigate the Pharmacokinetics and Safety of Tersolisib in Participants With Renal Impairment Compared With Participants With Normal Renal Function
Lead sponsor
Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
August 31, 2027
Enrollment
32 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participant, renal insufficiency

Arms

As registered; 3 arms.

  • Tersolisib Group 1 (Normal Renal Function) ExperimentalTersolisib

    Tersolisib administered orally to participants with normal renal function

  • Tersolisib Group 2 (Severe Renal Impairment) ExperimentalTersolisib

    Tersolisib administered orally to participants with severe renal impairment

  • Tersolisib Group 3 (Moderate Renal Impairment, Optional) ExperimentalTersolisib

    Tersolisib administered orally to participants with moderate renal impairment

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tersolisib Predose on Day 1 through Day 14
  • PK: Area Under the Concentration Versus Time Curve (AUC) of Tersolisib Predose on Day 1 through Day 14

Lead sponsor's other trials

Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, most recent start first.

Similar trials

Same condition (Renal Insufficiency, Chronic) and phase, most recent start first.